RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 91 filers reported holding RHYTHM PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $53,675,105 | -16.4% | 2,341,335 | -39.8% | 0.14% | -10.1% |
| Q2 2023 | $64,173,853 | -7.6% | 3,891,683 | 0.0% | 0.16% | -9.1% |
| Q1 2023 | $69,427,625 | -62.2% | 3,891,683 | -38.3% | 0.18% | -65.6% |
| Q4 2022 | $183,586,516 | +18.8% | 6,304,482 | -0.0% | 0.51% | +12.1% |
| Q3 2022 | $154,518,000 | +747.0% | 6,306,866 | +43.5% | 0.45% | +806.0% |
| Q2 2022 | $18,242,000 | -68.7% | 4,395,600 | -13.2% | 0.05% | -62.1% |
| Q1 2022 | $58,350,000 | +108.6% | 5,065,113 | +80.7% | 0.13% | +153.8% |
| Q4 2021 | $27,977,000 | -28.9% | 2,803,335 | -6.9% | 0.05% | -30.7% |
| Q3 2021 | $39,324,000 | -33.4% | 3,011,053 | -0.1% | 0.08% | -31.8% |
| Q2 2021 | $59,038,000 | -10.8% | 3,015,211 | -3.1% | 0.11% | -14.1% |
| Q1 2021 | $66,168,000 | -15.0% | 3,110,853 | +18.8% | 0.13% | -19.5% |
| Q4 2020 | $77,821,000 | +58.4% | 2,617,600 | +15.4% | 0.16% | +38.3% |
| Q3 2020 | $49,139,000 | -2.8% | 2,267,600 | +0.1% | 0.12% | -8.0% |
| Q2 2020 | $50,534,000 | +46.5% | 2,266,071 | +0.0% | 0.12% | +23.8% |
| Q1 2020 | $34,487,000 | -30.4% | 2,265,900 | +5.0% | 0.10% | -8.2% |
| Q4 2019 | $49,548,000 | +56.6% | 2,158,019 | +47.3% | 0.11% | +41.0% |
| Q3 2019 | $31,638,000 | +61.2% | 1,465,400 | +64.2% | 0.08% | +62.5% |
| Q2 2019 | $19,628,000 | -19.7% | 892,200 | 0.0% | 0.05% | -21.3% |
| Q1 2019 | $24,455,000 | +1.9% | 892,200 | -0.1% | 0.06% | -6.2% |
| Q4 2018 | $24,010,000 | +4.1% | 893,244 | +13.0% | 0.06% | +20.4% |
| Q3 2018 | $23,057,000 | +195.0% | 790,421 | +216.2% | 0.05% | +134.8% |
| Q2 2018 | $7,815,000 | +161.8% | 250,000 | +66.7% | 0.02% | +155.6% |
| Q1 2018 | $2,985,000 | -31.5% | 150,000 | 0.0% | 0.01% | -25.0% |
| Q4 2017 | $4,359,000 | – | 150,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
| NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
| Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
| Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
| VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
| RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
| Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
| Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
| Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |